Free Shipping in the U.S. for orders over $1000.  Shop Now>>

Recombinant MMP9 Matrix Metalloproteinase 9 (Papillary Thyroid Carcinoma Marker) Antibody [r15W2]

In Stock
Catalog Number Formulation Size Price
4318-MSM12-P0
Purified Ab with BSA and Azide at 200ug/ml
20ug
$249.00
4318-MSM12-P1
Purified Ab with BSA and Azide at 200ug/ml
100ug
$539.00
4318-MSM12-P1ABX
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
100ug
$539.00
Flat Rate Domestic: $75 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol Note
Immunohistochemistry (IHC)
1-2ug/ml
30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes

Summary

The matrix metalloproteinases (MMPs) are a family of zinc containing enzymes involved in the degradation of different components of the extracellular matrix and tissue remodelling. MMPs, which are expressed widely during growth and development, have been classified into collagenases, gelatinases and stromelysins, based on the in vitro substrate specificity. More recently several MMPs have been identified as membrane-type specific and matrilysin families. MMPs are multidomain proteins and are secreted as inactive precursors, which are activated by cleavage of an N-terminal pro-peptide. The major natural inhibitors of MMPs are tissue inhibitors of matrix metalloproteinases (TIMPs) which complex with MMPs and are involved in regulating the activity and activation of individual MMPs. MMP9 degrades collagen type IV, a major component of extracellular matrix. MMP9 is also reported to be observed immunohistochemically in normal kidney tubules, hepatocytes, spermatids, myocytes, stomach parietal cells, prostatic columnar epithelium and uterine cells.

Product Properties & Targets

Host
Mouse
Applications
Species Reactivity
Isotype / Light Chain
IgG2a / Kappa
Cellular Localization
Extracellular matrix, Extracellular space, Secreted
Gene Name
Positive Control
Human spleen tissue or human heart tissue.
Immunogen
Prokaryotic recombinant protein corresponding to a 134 amino acid portion of the C-terminal region of the mature human MMP9 molecule
Alternate Names
Matrix metalloproteinase-9, 92 kDa gelatinase, 92 kDa type IV collagenase, Gelatinase B, 82 kDa matrix metalloproteinase-9; 92 kDa type IV collagenase; CLG 4B; CLG4B; Collagenase Type 4 beta; Collagenase type IV 92 KD; EC 3.4.24.35; Gelatinase 92 KD; Gelatinase B; Gelatinase beta; GELB; Macrophage gelatinase; MANDP2;

Database Links

Entrez Gene ID
SwissProt

Additional Information

Clone
r15W2
Chromosome Location
20q13.12
Mol. Weight of Antigen
92kDa

Functions

  • Matrix metalloproteinase that plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration (PubMed:2551898, PubMed:1480034, PubMed:12879005). Could play a role in bone osteoclastic resorption (By similarity). Cleaves KiSS1 at a Gly-
  • -Leu bond (PubMed:12879005). Cleaves NINJ1 to generate the Secreted ninjurin-1 form (PubMed:32883094). Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments (PubMed:1480034). Degrades fibronectin but not laminin or Pz-peptide.

Key References

  • Thanakit V, Sampatanukul P, Ruangvejvorachai P, Keelawat S. J Med Assoc Thai. 2005 Sep;88 Suppl 4:S30-5.
  • Elsasser, A., et al. 2004. J. Am. Coll. Cardiol. 43: 2191-2199.
  • El-Shabrawi Y, Ardjomand N, Radner H, et al. Journal of Pathology. 194: 201–206 (2001).
  • Lechapt-Zalcman E, Coste A, d’Ortho M P, et al. Journal of Pathology. 193: 233–241 (2001).
  • Soini Y, Satta J, Määttä M, et al,. Journal of Pathology. 194: 225–231 (2001).
  • Flavell J R, Baumforth K R N, Williams D M, et al. Molecular Pathology. 53: 145–149 (2000).
  • Horikawa T, Yoshizaki T, Sheen T-S, et al. Cancer. 89 (4): 715–723 (2000).
  • Dumas V, Kanitakis J, Charvat S, et al. Anticancer Research. 19 (4B): 2929–2938 (1999).
  • Kanbe N, Tanaka A, Kanbe M, et al. European Journal of Immunology. 29 (8): 2645–2649 (1999).
  • Kossakowska A E, Huchcroft S A, Urbanski S J, et al. British Journal of Cancer. 73: 1401–1408 ).
  • (1996).
  • Ueda Y, Imai K, Tsuchiya H, et al. American Journal of Pathology. 148 (2): 611–622 (1996).
  • Okada Y, Gonoji Y, Naka K, et al. The Journal of Biological Chemistry. 267 (30): 21712–21719 (1992).

Storage & Stability

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations

This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab produced in CHO cell mammalian-based expression system. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Warranty

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

Reviews

There are no reviews yet.

Be the first to review “Recombinant MMP9 Matrix Metalloproteinase 9 (Papillary Thyroid Carcinoma Marker) Antibody”

Your email address will not be published. Required fields are marked *

PARTNERSHIP OPPORTUNITIES

NeoBiotechnologies holds Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK